# Odyssey Therapeutics, Inc. Common Stock (ODTX)

> Odyssey Therapeutics, Inc. Common Stock (ODTX) trades at $18.98 (-2.01%) as of 4:20:00 PM EST on Nov 18, 2026, -0.05% over the past month. Market cap is $912.33M, with 15.4 days to cover in short interest.

Canonical: https://massive.com/quote/odtx
Data as of: 2026-11-18T21:20:00.431Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$18.98** -0.39 (-2.01%)
As of 4:20:00 PM EST on Nov 18, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Odyssey Therapeutics, Inc. Common Stock (ODTX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -2.01% |
| 1W | -9.58% |
| 1M | -0.05% |
| YTD | +15.59% |
| 1Y | +15.59% |
| 52-wk range | $15.10 – $29.05 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for ODTX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $18.81 – $19.98 |
| Open | $19.26 |
| Prev close | $19.37 |
| Volume | 369.1K |
| Market cap | $912.33M |
| Shares out | 48.07M |

## Valuation and profitability ratios

Valuation and profitability ratios for Odyssey Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 2.43 |
| P/FCF | — |
| ROE | -38.4% |
| ROA | -32.9% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 18, 2026

## Insider trading

[Odyssey Therapeutics, Inc. Common Stock (ODTX) insider trading](https://massive.com/quote/odtx/insider-trading.md): open-market Form 4 buys and sells by Odyssey Therapeutics, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Odyssey Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 4, 2026, Odyssey Therapeutics, Inc. (the "Company") announced its financial results for the three months ended September 30, 2026.”
- Oct 20, 2026 · Investor presentation
  “The Company issued the press release and “posted a corporate presentation on its website at https://investors.odysseytx.com/news-events/presentations.””
- Sep 9, 2026 · Investor presentation
  “On September 8, 2026, Odyssey Therapeutics, Inc. (the "Company") posted a corporate presentation on its website at https://investors.odysseytx.com/news-events/presentations. A copy of the presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.”
- Jun 23, 2026 · Investor presentation
  “On June 23, 2026, Odyssey Therapeutics, Inc. (the "Company") posted a corporate presentation on its website at https://investors.odysseytx.com/news-events/presentations. A copy of the presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.”
- May 11, 2026 · Charter amendment
  “In connection with the closing of the IPO, on May 11, 2026, the Company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware. The Company's board of directors and stockholders previously approved the Amended and Restated Certificate of Incorporation to be effective as of immediately prior to the closing of the IPO.”

## ODTX short interest

How heavily ODTX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 15.4 |
| Short interest | 3.35M |
| Avg volume | 216.97K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## About Odyssey Therapeutics, Inc. Common Stock

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Listed | May 8, 2026 |

[Company website](https://www.odysseytx.com)

## FAQ

### What is the Odyssey Therapeutics, Inc. Common Stock (ODTX) stock price today?

Odyssey Therapeutics, Inc. Common Stock (ODTX) is trading at $18.98 (-2.01% on the day) as of 4:20:00 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Odyssey Therapeutics, Inc. Common Stock?

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases.

### What is the short interest in ODTX?

As of Oct 30, 2026, ODTX has 3.35M shares short and 15.4 days to cover.

### What exchange is ODTX listed on?

Odyssey Therapeutics, Inc. Common Stock (ODTX) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time ODTX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ODTX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Odyssey Therapeutics, Inc. Common Stock (ODTX) insider trading](https://massive.com/quote/odtx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
